Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2014

01-04-2014 | Preclinical study

Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers

Authors: Weiwei Shi, Balint Balazs, Balazs Györffy, Tingting Jiang, W. Fraser Symmans, Christos Hatzis, Lajos Pusztai

Published in: Breast Cancer Research and Treatment | Issue 3/2014

Login to get access

Abstract

The goal of this analysis was to develop a computational tool that integrates the totality of gene expression, DNA copy number, and sequence abnormalities in individual cancers in the framework of biological processes. We used the hierarchical structure of the gene ontology (GO) database to create a reference network and projected mRNA expression, DNA copy number and mutation anomalies detected in single samples into this space. We applied our method to 59 breast cancers where all three types of molecular data were available. Each cancer had a large number of disturbed biological processes. Locomotion, multicellular organismal process, and signal transduction pathways were the most commonly affected GO terms, but the individual molecular events were different from case-to-case. Estrogen receptor-positive and -negative cancers had different repertoire of anomalies. We tested the functional impact of 27 mRNAs that had overexpression in cancer with variable frequency (<2–42 %) using an siRNA screen. Each of these genes inhibited cell growth in at least some of 18 breast cancer cell lines. We developed a free, on-line software tool (http://​netgoplot.​org) to display the complex genomic abnormalities in individual cancers in the biological framework of the GO biological processes. Each cancer harbored a variable number of pathway anomalies and the individual molecular events that caused an anomaly varied from case-to-case. Our in vitro experiments indicate that rare case-specific molecular abnormalities can play a functional role and driver events may vary from case-to-case depending on the constellation of other molecular anomalies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cao Y, DePinho RA, Ernst M, Vousden K (2011) Cancer research: past, present and future. Nat Rev Cancer 11:749–754PubMedCrossRef Cao Y, DePinho RA, Ernst M, Vousden K (2011) Cancer research: past, present and future. Nat Rev Cancer 11:749–754PubMedCrossRef
3.
go back to reference Thomas RK et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–351PubMedCrossRef Thomas RK et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–351PubMedCrossRef
6.
go back to reference Vaske CJ et al (2010) Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26:237–245CrossRef Vaske CJ et al (2010) Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26:237–245CrossRef
7.
go back to reference Kamada T, Kawai S (1989) An algorithm for drawing general undirected graphs. Inf Process Lett (Elsevier) 31:7–15CrossRef Kamada T, Kawai S (1989) An algorithm for drawing general undirected graphs. Inf Process Lett (Elsevier) 31:7–15CrossRef
8.
go back to reference Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557–572PubMedCrossRef Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557–572PubMedCrossRef
10.
go back to reference Iwamoto T, Bianchini G, Booser D, Qi Y et al (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103(3):264–272PubMedCrossRef Iwamoto T, Bianchini G, Booser D, Qi Y et al (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103(3):264–272PubMedCrossRef
11.
go back to reference Andre F et al (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15:441–451PubMedCrossRef Andre F et al (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15:441–451PubMedCrossRef
12.
go back to reference Nekrutenko A, Taylor J (2012) Next-generation sequencing data interpretation: enhancing reproducibility and accessibility. Nat Rev Genet 13:667–672 Nekrutenko A, Taylor J (2012) Next-generation sequencing data interpretation: enhancing reproducibility and accessibility. Nat Rev Genet 13:667–672
13.
go back to reference Wang K, Li M, Hakonarson H (2010) Annovar: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38(16):e164PubMedCentralPubMedCrossRef Wang K, Li M, Hakonarson H (2010) Annovar: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38(16):e164PubMedCentralPubMedCrossRef
14.
go back to reference Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39(17):e118PubMedCentralPubMedCrossRef Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39(17):e118PubMedCentralPubMedCrossRef
15.
go back to reference Ng PC, Henikoff S (2006) Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7:61–80PubMedCrossRef Ng PC, Henikoff S (2006) Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7:61–80PubMedCrossRef
17.
go back to reference Torkamani A, Schork NJ (2008) Prediction of cancer driver mutations in protein kinases. Cancer Res 68:1675–1682PubMedCrossRef Torkamani A, Schork NJ (2008) Prediction of cancer driver mutations in protein kinases. Cancer Res 68:1675–1682PubMedCrossRef
18.
go back to reference Torkamani A, Schork NJ (2007) Accurate prediction of deleterious protein kinase polymorphisms. Bioinformatics 23:2918–2925PubMedCrossRef Torkamani A, Schork NJ (2007) Accurate prediction of deleterious protein kinase polymorphisms. Bioinformatics 23:2918–2925PubMedCrossRef
Metadata
Title
Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers
Authors
Weiwei Shi
Balint Balazs
Balazs Györffy
Tingting Jiang
W. Fraser Symmans
Christos Hatzis
Lajos Pusztai
Publication date
01-04-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-2904-z

Other articles of this Issue 3/2014

Breast Cancer Research and Treatment 3/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine